AC
TVTX icon

Athanor Capital’s Travere Therapeutics TVTX Stock Holding History

Athanor Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-28,813
Closed -$719K – 762
2021
Q1 		$719K Buy
28,813
+5,487
+24% +$152K 0.02% 407
2020
Q4 		$636K Buy
23,326
+6,948
+42% +$162K 0.01% 419
2020
Q3 		$302K Sell
16,378
-8,022
-33% -$156K 0.01% 428
2020
Q2 		$498K Buy
+24,400
New +$389K 0.03% 306
2020
Q1 		– Sell
-18,256
Closed -$259K – 334
2019
Q4 		$259K Buy
+18,256
New +$233K 0.01% 326

Other funds holding TVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Athanor Capital's TVTX Position: Q2 2021 in Review

Athanor Capital sold out of Travere Therapeutics (TVTX) in Q2 2021, closing a stake of 28,813 shares — an estimated $719K sold.

Athanor Capital first reported a position in TVTX in Q4 2019 and held it in 5 quarters. The position peaked at $719K in Q1 2021. 136 funds tracked by Wall St. Rank hold TVTX as of Q2 2021.

  • Athanor Capital reported no remaining Travere Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Athanor Capital sold 28,813 Travere Therapeutics shares in Q2 2021, an estimated $719K.
  • Athanor Capital first reported a position in Travere Therapeutics in Q4 2019 and held it in 5 quarters.
  • Athanor Capital's Travere Therapeutics position peaked at $719K in Q1 2021.
  • 136 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2021.

Based on Athanor Capital's 13F filing for Q2 2021, filed 16 Aug 2021.